Literature DB >> 18518885

Alveolar-arterial oxygen gradient, pneumonia severity index and outcomes in patients hospitalized with community acquired pneumonia.

Mahmoud Q Moammar1, Hamad M Azam, Adel I Blamoun, Ashraf O Rashid, Medhat Ismail, M Anees Khan, Vincent A DeBari.   

Abstract

The alveolar-arterial oxygen gradient (DeltaA-a) provides a useful assessment of ventilation/perfusion (V/Q) abnormalities. The objectives of the present study were to: (i) examine the correlation between the DeltaA-a and the pneumonia severity index (PSI); and (ii) determine whether these measures were comparable in predicting clinical outcomes. The present study was conducted at a 750-bed teaching hospital. It examined a retrospective cohort of 255 patients with community acquired pneumonia (CAP) over a 2 year period. Association between the CAP and DeltaA-a was investigated by regression models and correlation, as well as two logistic models for subjects bifurcated by low-risk/moderate-to-high risk. The decision levels (DL) for both PSI and DeltaA-a were then compared as predictors of both length of stay (LOS) and survival. The correlation between PSI and DeltaA-a was strong (rho = 0.76; P < 0.0001) and was best modelled by a curvilinear relationship. Both logistic models indicated a strong association (P < 0.001) between DeltaA-a and PSI and yielded an optimal DL for the DeltaA-a of < 89 mmHg. Inter-test agreement of DeltaA-a with PSI was 76.9% (kappa = 0.60; 95% confidence interval 0.47-0.72; P < 0.0001). At < 89 mmHg, the odds ratios for LOS were similar to those at PSI = 90 in predicting LOS in the range 3-7 days, inclusive. There was no significant difference in the ability of DeltaA-a and PSI to predict survival for either the low- or high-risk group (P = 0.363 and P = 0.951, respectively). The DeltaA-a correlates well with PSI and performs comparably in predicting two major outcomes in subjects hospitalized with CAP.

Entities:  

Mesh:

Year:  2008        PMID: 18518885     DOI: 10.1111/j.1440-1681.2008.04971.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

1.  Alveolar Arterial Gradient and Respiratory Index in Predicting the Outcome of COVID-19 Patients; a Retrospective Cross-Sectional Study.

Authors:  Abhishek Singh; Kapil Dev Soni; Yudhyavir Singh; Richa Aggarwal; Vineeta Venkateswaran; Mohd Suhail Ashar; Anjan Trikha
Journal:  Arch Acad Emerg Med       Date:  2022-04-14

2.  Can Alveolar-Arterial Difference and Lung Ultrasound Help the Clinical Decision Making in Patients with COVID-19?

Authors:  Gianmarco Secco; Francesco Salinaro; Carlo Bellazzi; Marco La Salvia; Marzia Delorenzo; Caterina Zattera; Bruno Barcella; Flavia Resta; Giulia Vezzoni; Marco Bonzano; Giovanni Cappa; Raffaele Bruno; Ivo Casagranda; Stefano Perlini
Journal:  Diagnostics (Basel)       Date:  2021-04-23

3.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

4.  Chest computed tomography and alveolar-arterial oxygen gradient as rapid tools to diagnose and triage mildly symptomatic COVID-19 pneumonia patients.

Authors:  Marlise P de Roos; Iris D Kilsdonk; Pieter-Paul W Hekking; Jan Peringa; Nynke G Dijkstra; Peter W A Kunst; Paul Bresser; Herre J Reesink
Journal:  ERJ Open Res       Date:  2021-03-08

5.  Impact of cytidine diphosphocholine on oxygenation in client-owned dogs with aspiration pneumonia.

Authors:  Anda A Young; Lucia E Rosas; Edward S Cooper; Page E Yaxley; Ian C Davis
Journal:  J Vet Intern Med       Date:  2022-04-29       Impact factor: 3.175

Review 6.  Cardiopulmonary Pathophysiological Aspects in the Context of COVID-19 and Obesity.

Authors:  Abdallah Fayssoil; Marie Charlotte De Carne De Carnavalet; Nicolas Mansencal; Frederic Lofaso; Benjamin Davido
Journal:  SN Compr Clin Med       Date:  2021-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.